Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Edaravone showed a good effect on promoting remyelination and protecting axons in NMOSD animals. We hypothesize that edaravone can inhibit axonal damage in patients with aquaporin-4 Antibody-positive Optic Neuritis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital of Guangxi Medical University
• Treatments: Edaravone

Criteria

Inclusion Criteria:

1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis

2. Patients with a first episode of optic neuritis in either eye

3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone

Exclusion Criteria:

1. Myopia over 6 diopters

2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity